We look forward to welcoming Dr. Thomas Hope from UCSF. Dr. Hope’s main research focus is on novel imaging agents. He is the lead investigator on the Ga-68 DOTA-TOC IND at UCSF.
We look forward to seeing you at our October 3rd meeting. Our meetings are held from 1-4pm at the Cancer Support Community (CSC), located at 3276 Mc Nutt Avenue, Walnut Creek, CA. For more information visit our meeting page online.
Now On-Line:
2016 Regional Conference Topic Survey: At our August meeting we discussed some possiable topics for our 2016 regional conference. We have put a quick online survey (less than 5 minutes to complete) so we can better understand the topics our community would like to hear about. Please fill out the survey no later than 8/23/15 so that we can include our voice in the conference planning.
2015 Warner Advocay Award Nomination: Presented by Novartis Oncology through Patient Advocacy and The NET Alliance, the 2015 Warner Advocacy Award will be given to the individual who best embodies the spirit, passion, and dedication of Monica Warner. Nominees may be patients, caregivers, or advocates who work in the United States. Nominations are open through 8/20/15.
Lexicon Pharmaceuticals, Inc. announced that the pivotal TELESTAR Phase III clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. If approved, telotristat etiprate would be the first oral treatment successfully developed for carcinoid syndrome and the first addition to the standard of care in more than 16 years.